The trajectory of Viagra, formerly marketed by copyright, presents a fascinating case study for investors considering the healthcare sector. Despite its early success and generation of billions in revenue , the intellectual property expiration has opened the floodgates for competing medications, greatly eroding income opportunities. This change rai